What Orforglipron Is
Orforglipron is an oral, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike the injectable peptide GLP-1-class compounds (semaglutide, tirzepatide, retatrutide), orforglipron is a non-peptide chemical entity that is orally bioavailable as a once-daily tablet — with no injection, no reconstitution, and no food or water timing restrictions. Eli Lilly markets it under the brand name Foundayo.
| Fact | Value | Primary source |
|---|---|---|
| Compound class | Oral small-molecule GLP-1 receptor agonist (non-peptide) | Eli Lilly |
| Developer | Eli Lilly & Company | investor.lilly.com |
| Administration | Once-daily oral tablet; no food/water restriction | Eli Lilly (Foundayo approval release) |
| Brand name | Foundayo | Eli Lilly / FDA (2026) |
| Pivotal obesity trial (no T2D) | ATTAIN-1 (Phase 3, 72 weeks) | Wharton, Aronne, Stefanski et al., NEJM 2026 |
| Obesity + T2D trial | ATTAIN-2 (Phase 3) | The Lancet (ATTAIN-2) |
| Head-to-head vs oral semaglutide | ACHIEVE-3 (Phase 3, T2D) | The Lancet (ACHIEVE-3) |
RetaLABS does not supply orforglipron. This page is provided purely as an informational research reference. Orforglipron is the subject of an approved therapeutic product in some jurisdictions; that is legally and pharmacologically distinct from the research-grade peptides RetaLABS supplies for laboratory use only.
Mechanism — Oral, Non-Peptide GLP-1 Agonism
GLP-1 receptor agonism — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central satiety signalling — is the same mechanism shared by semaglutide, the GLP-1 component of tirzepatide, and orforglipron. What distinguishes orforglipron is the molecule itself: it is a small-molecule, non-peptide agonist rather than an engineered peptide.
Peptide GLP-1 agonists are degraded in the gastrointestinal tract, which is why semaglutide, tirzepatide and retatrutide are injected (oral semaglutide exists but requires an absorption enhancer and strict fasted-state, water-restricted dosing). A small-molecule agonist is chemically stable enough to be absorbed orally without those constraints — orforglipron can be taken at any time of day, with or without food or water. For research workflows, the practical contrast is stark: there is no reconstitution step, no bacteriostatic water, no cold-chain handling of a solution, and no subcutaneous administration — considerations that dominate the handling of injectable peptide compounds (see the peptide reconstitution and storage guide).
Phase 3 Weight-Loss Data (ATTAIN-1 and ATTAIN-2)
ATTAIN-1 (obesity without type 2 diabetes; Wharton, Aronne, Stefanski et al., NEJM 2026, DOI 10.1056/NEJMoa2511774) was a 72-week, randomised, double-blind, placebo-controlled Phase 3 trial of once-daily orforglipron at 6mg, 12mg, or 36mg versus placebo. At the highest dose (36mg), mean weight loss was approximately 12.4% (about 27.3 lb) at 72 weeks; 59.6% of participants on the highest dose lost at least 10% of body weight and 39.6% lost at least 15%.
ATTAIN-2 (obesity in people with type 2 diabetes; The Lancet) reported mean weight loss of about 10.5% at the 36mg dose (5.5% at 6mg, 7.8% at 12mg), versus ~2.2% for placebo — consistent with the well-documented pattern that weight loss in a type-2-diabetes population is somewhat attenuated relative to obesity-without-diabetes cohorts across the GLP-1 class.
| Trial | Population | Top dose | Mean weight loss | Endpoint |
|---|---|---|---|---|
| ATTAIN-1 | Obesity, no T2D | 36mg/day | ~12.4% | 72 weeks |
| ATTAIN-2 | Obesity + T2D | 36mg/day | ~10.5% | Phase 3 endpoint |
Head-to-Head: ACHIEVE-3 vs Oral Semaglutide
ACHIEVE-3 (The Lancet) is notable because it is a genuine head-to-head Phase 3 trial — orforglipron directly against oral semaglutide in adults with type 2 diabetes inadequately controlled on metformin (~1,698 participants, 52 weeks, open-label). Orforglipron produced greater reductions in both HbA1c and body weight than oral semaglutide:
| Arm | HbA1c reduction | Weight loss | AE-driven discontinuation |
|---|---|---|---|
| Orforglipron 12mg | ~1.71 pts | ~6.7% | ~8.7% |
| Orforglipron 36mg | ~1.91 pts | ~9.2% | ~9.7% |
| Oral semaglutide 7mg | ~1.23 pts | ~3.7% | ~4.5% |
| Oral semaglutide 14mg | ~1.47 pts | ~5.3% | ~4.9% |
The trade-off visible in the table is that orforglipron's stronger glycaemic and weight effects came with higher adverse-event-driven discontinuation (~8.7–9.7% vs ~4.5–4.9% for oral semaglutide), driven by the gastrointestinal events (nausea, diarrhoea, vomiting, decreased appetite) characteristic of the GLP-1 class. Because ACHIEVE-3 is head-to-head, its comparison is directly controlled — distinct from the cross-trial comparisons used elsewhere on this site for the injectable obesity trials.
Orforglipron vs the Injectable GLP-1 Class (Cross-Trial)
Comparing orforglipron's obesity result to the injectable peptide compounds is cross-trial and observational — not head-to-head. The studies differ in population, duration, route, and design, so the figures below provide context, not a ranking.
| Compound | Route | Top-dose weight loss | Trial / endpoint |
|---|---|---|---|
| Orforglipron | Oral tablet (daily) | ~12.4% | ATTAIN-1, 72 wk |
| Semaglutide | Injectable (weekly) | 14.9% | STEP 1, 68 wk |
| Tirzepatide | Injectable (weekly) | 20.9% | SURMOUNT-1, 72 wk |
| Retatrutide | Injectable (weekly) | 25.0% | TRIUMPH-1, 80 wk |
The pattern across the class is that the injectable multi-receptor peptides (tirzepatide's GLP-1/GIP, retatrutide's GLP-1/GIP/glucagon) report larger mean reductions than the single-receptor GLP-1 agonists, while orforglipron's distinguishing advantage is route — an oral tablet rather than a weekly injection. Comparator data: STEP 1 semaglutide (Wilding et al., NEJM 2021), SURMOUNT-1 tirzepatide (Jastreboff et al., NEJM 2022), and the retatrutide TRIUMPH-1 readout. No head-to-head trial of orforglipron against any injectable obesity compound has been reported.
Regulatory Status (2026)
In 2026 the United States FDA approved orforglipron under the brand name Foundayo for chronic weight management in adults with obesity, or overweight with at least one weight-related condition — described by Eli Lilly as the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions. The approval followed the ATTAIN Phase 3 programme.
| Jurisdiction | Status (2026) |
|---|---|
| United States (FDA) | Approved as Foundayo (orforglipron) for chronic weight management |
| Australia (TGA) | No orforglipron product is listed on the Australian Register of Therapeutic Goods as of this writing; treat as not TGA-approved unless the ARTG confirms otherwise |
RetaLABS does not supply orforglipron and makes no therapeutic claim about it. The Australian regulatory position should be confirmed against the current TGA / ARTG register — a US FDA approval does not by itself confer Australian approval. This page is an informational research reference only and is not medical advice.